Arthritis research & therapy
Real-world comparative effectiveness of sarilumab versus Janus kinase inhibitors as monotherapy in rheumatoid arthritis.
Yuji Nozaki, Kazuya Kishimoto, Tetsu Itami, Daisuke Tomita, Yumiko Wada, Takuya Kotani, Tohru Takeuchi, Toshihiko Hidaka, Shoichi Hino, Toshiaki Miyamoto, Hirofumi Miyake, Kazunari Hatta, Kenji Mamoto, Yutaro Yamada, Tadashi Okano
Published: 202610.1186/s13075-025-03722-5
Abstract
BACKGROUND: Sarilumab (SAR), an interleukin-6 receptor inhibitor (IL-6Ri), and Janus kinase inhibitors (JAKi) are approved options for rheumatoid arthritis (RA) when methotrexate (MTX) cannot be used. Real-world evidence for MTX-free monotherapy rema…
Preview only. Read the full abstract at the source